Clinical Trials Logo

Clinical Trial Summary

This phase II trial is studying how well AZD2171 works in treating patients with locally advanced unresectable or metastatic liver cancer. AZD2171 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor


Clinical Trial Description

PRIMARY OBJECTIVE:

I. Assess the progression free survival of patients with locally advanced unresectable or metastatic hepatocellular carcinoma treated with AZD2171.

SECONDARY OBJECTIVES:

I. Determine the toxicity of this drug in these patients. II. Determine, preliminarily, the efficacy of this drug, in terms of response rate, duration of response, and overall survival, in these patients.

III. Determine the blood flow changes and vascular permeability of the tumor in patients treated with this drug.

IV. Determine the pharmacokinetic profile of this drug in these patients.

OUTLINE: This is a multicenter study.

Patients receive oral AZD2171 once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Dynamic contrast-enhanced (DCE) MRI and CT perfusion scan of the liver are performed at baseline, 72 hours after the initial dose of AZD2171, and at the end of course 1. Blood samples for pharmacokinetic studies are collected periodically during study.

After the completion of study treatment, patients are followed every 3 months for 1 year. ;


Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms

  • Adult Primary Hepatocellular Carcinoma
  • Advanced Adult Primary Liver Cancer
  • Carcinoma, Hepatocellular
  • Liver Neoplasms
  • Localized Unresectable Adult Primary Liver Cancer
  • Recurrent Adult Primary Liver Cancer

NCT number NCT00427973
Study type Interventional
Source National Cancer Institute (NCI)
Contact
Status Terminated
Phase Phase 2
Start date May 2009

See also
  Status Clinical Trial Phase
Terminated NCT00787787 - Sunitinib Malate and Capecitabine in Treating Patients With Unresectable or Metastatic Liver Cancer Phase 2
Completed NCT00052364 - Oxaliplatin in Treating Patients With Liver Cancer Phase 2
Completed NCT01229111 - Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary Cancers Phase 2
Completed NCT00107536 - Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer Phase 2
Completed NCT02072356 - Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot be Removed by Surgery Early Phase 1
Completed NCT00604721 - Selumetinib in Treating Patients With Locally Advanced or Metastatic Liver Cancer Phase 2
Completed NCT00101036 - Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery Phase 2
Completed NCT00028496 - Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer Phase 1
Completed NCT01766219 - CPI-613 in Treating Patients With Advanced or Metastatic Bile Duct Cancer That Cannot Be Removed By Surgery Phase 1/Phase 2
Completed NCT00321594 - Belinostat in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery Phase 1/Phase 2
Terminated NCT00087191 - EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer N/A
Completed NCT00006016 - Thalidomide and Chemoembolization With Doxorubicin in Treating Patients With Liver Cancer That Cannot be Removed by Surgery Phase 2
Completed NCT01643499 - Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies Phase 1
Completed NCT00639509 - IMC-A12 in Treating Patients With Advanced Liver Cancer Phase 2
Completed NCT00083226 - Doxorubicin and Bortezomib in Treating Patients With Liver Cancer Phase 2
Completed NCT00033462 - Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer Phase 2
Completed NCT01666756 - Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer Phase 1
Active, not recruiting NCT02119065 - Pilot Study to Assess Lung Shunting of Yttrium-90 Microspheres Using PET/CT
Recruiting NCT02557503 - Hepatic Arterial Infusion of Oxaliplatin and Fluorouracil Treatment of Advanced Primary Liver Cancer After TACE Phase 4
Withdrawn NCT01859182 - Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By Surgery Phase 2